Latest News for: masp
Edit
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) (Form 8-K) (Omeros Corporation)
Public Technologies 01 Dec 2025
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) ... MASP-3 is responsible for converting complement pro-factor D to its active form, factor D.
Edit
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor ...
Nasdaq Globe Newswire 15 Oct 2025
.
Edit
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906) (Form 8-K) (Omeros Corporation)
Public Technologies 15 Oct 2025
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906) ... MASP-3 is responsible for converting complement pro-factor D to its active form, factor D.
- 1